Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Invested Capital (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Invested Capital readings, the most recent being $463.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 102.95% year-over-year to $463.8 million, compared with a TTM value of $463.8 million through Dec 2025, up 102.95%, and an annual FY2025 reading of $463.8 million, up 102.95% over the prior year.
  • Invested Capital hit $463.8 million in Q4 2025 for Apellis Pharmaceuticals, down from $494.7 million in the prior quarter.
  • The five-year high for Invested Capital was $494.7 million in Q3 2025, with the low at -$141.5 million in Q2 2021.
  • Median Invested Capital over the past 5 years was $234.7 million (2023), compared with a mean of $239.3 million.
  • The sharpest move saw Invested Capital tumbled 160.97% in 2021, then soared 794.8% in 2022.
  • Year by year, Invested Capital stood at $198.7 million in 2021, then fell by 14.49% to $169.9 million in 2022, then increased by 14.51% to $194.5 million in 2023, then grew by 17.49% to $228.5 million in 2024, then soared by 102.95% to $463.8 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $463.8 million, $494.7 million, and $156.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.